Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How to optimize HCV therapy in genotype 1 patients with cirrhosis.

Liver international : official journal of the International Association for the Study of the Liver - 1 Feb 2013

Bourlière Marc, Wendt Astrid, Fontaine Hélène, Hézode Christophe, Pol Stanislas, Bronowicki Jean Pierre

Abstract excerpt

Of all hepatitis C virus patients, those with cirrhosis are most in need of treatment owing to increased morbidity and mortality. Treatment with pegylated interferon and ribavirin (PEG-IFN/RBV) has clearly shown the benefits of successful treatment by improving fibrosis, causing the regression of cirrhosis and reducing and preventing cirrhosis-related complications. However, the sustained virological response...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Interferon-alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon alpha-2

Share to Liver Cirrhosis

Share to Patient Selection

Share to Polyethylene Glycols

Share to Ribavirin

Share to Serine Proteinase Inhibitors

Source

Identifiers

PMID: 23286846
DOI: 10.1111/liv.12067

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How to optimize HCV therapy in genotype 1 patients with cirrhosis.PMID 23286846Read ↗

How to optimize HCV therapy in genotype 1 patients: predictors of response.Semantic proximity Read ↗

Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.Semantic proximity Read ↗

Management of HCV in cirrhosis-a rapidly evolving landscape.Semantic proximity Read ↗

Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.Semantic proximity Read ↗

Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.Semantic proximity Read ↗

How to optimize HCV therapy in genotype 2 patients.Semantic proximity Read ↗

Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?Semantic proximity Read ↗

Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients.Semantic proximity Read ↗

[Triple therapy in cirrhotic patients and those with advanced fibrosis: relevant aspects in clinical practice].Semantic proximity Read ↗

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.Semantic proximity Read ↗

How to optimize HCV therapy in genotype 4 patients.Semantic proximity Read ↗

Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.